Investors

Autifony Therapeutics Limited is a privately funded company. The main investors are:

SV Life Sciences

SV Life Sciences

SV Life Sciences is a leading international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994. The SVLS team manages five venture capital funds and a publicly traded investment trust with approximately $2 billion of capital under management. The firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services. SVLS has offices in Boston, London and San Francisco.

Imperial Innovations

Imperial Innovations

Imperial Innovations was founded in 1986 as the technology transfer office of Imperial College London and was admitted to the AIM of the London Stock Exchange in 2006. Until 2011, Innovations invested only in companies based on intellectual property developed at Imperial College. In January of that year, the company raised 140 million to invest in businesses built on intellectual property developed at or associated with the Universities of Cambridge and Oxford and University College London, in addition to Imperial College London. Since admission to AIM in 2006, we have raised over 200 million to invest in and grow technology and healthcare businesses based on pioneering academic research. Innovations have invested over 121 million in this time, and their portfolio of companies has raised over 408 million.

Pfizer Venture Investments

Pfizer Venture Investments

Pfizer Venture Investments (PVI), the venture capital arm of Pfizer Inc., was founded in 2004 and invests for return in areas of current or future strategic interest to Pfizer. As part of Worldwide Business Development, PVI seeks to remain at the forefront of life science advances, looking to identify and invest in emerging companies that are developing compounds and technologies that have the potential to enhance Pfizer's pipeline and shape the future of the pharmaceutical industry. PVI invests in companies at any stage of development, with a strong focus on growth stage opportunities and is actively seeking to make new investments in a broad array of healthcare related areas, including therapeutics, platform technologies, diagnostics, drug delivery, pharmaceutical services, healthcare IT, and other technologies impacting drug discovery and development.

Additional Funding

Additional Funding for Autifony has also been obtained from UCL Business and from The International Biotechnology Trust (IBT).